Clinical trial · Interventional
Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy
Effect of Omega-3 Supplementation on Body Composition, Functional Capacity, Inflammatory Profile and Quality of Life in Cervix Cancer Patients Undergoing Chemoradiotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cancer cachexia is a complex metabolic process affecting up to 80% of patients suffering from an advanced-stage cancer. Moreover, 20 to 40% of all cancer deaths are caused directly by cachexia. Recently, omega-3 fatty acids have gained interest for their beneficial effects in cancer cachexia. Moreover, nutritional supplementation enriched with omega-3 could potentially maintain body weight in cancer patients undergoing intensive treatment. The investigators aims in this study is to evaluate the effect of omega-3 supplementation on body composition, functional capacity, inflammatory profile and quality of life in cervix cancer patients undergoing chemoradiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcopenia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Olive oil | Dietary Supplement | — | UNRESOLVED |
| Omega-3 | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Omega-3
- description
- Group who will receive 2g eicosapentaenoic (4 capsules) acid per day during the chemoradiotherapy protocol.
- interventionNames
- Dietary Supplement: Omega-3
- type
- PLACEBO_COMPARATOR
- label
- Olive oil
- description
- Group who will receive olive oil per day (4 capsules) during the chemoradiotherapy protocol.
- interventionNames
- Dietary Supplement: Olive oil
Primary outcomes (1)
- measure
- Change in Body composition
- timeFrame
- 45 days
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 59 Years
Show eligibility criteria text
Inclusion Criteria: * Cervix cancer at FIGO stage II and III * Chemoradiotherapy treatment proposal (cisplatin + radiotherapy) * Nutritional diagnosis of pre-cachexia ou cachexia Exclusion Criteria: * metastasis (FIGO stage IV) * Nutritional diagnosis of refractary cachexia
References
Publications (0)
Data not yet available